- Trial phase
- Early clinical (Phase 1-type); no Phase 2/3 trial yet
- Time to market
- Unknown, likely several years away: the drug is in early clinical (Phase 1-type) testing as of mid-2026, with no registrational trial started.
- Why 3/10
- No hard, dated binary catalyst for ACR-2316 is scheduled in the next ~12 months, only scientific-conference data updates on its ongoing early clinical (Phase 1-type) program, and the company's dated 2H 2026 catalyst belongs to lead asset ACR-368's Phase 2b interim, so ACR-2316 rates low (3) on the impact scale.
ACR-2316 is a longer-dated option inside Acrivon: watch for quantitative response/tolerability numbers from its ongoing Phase 1 dose escalation at oncology congresses, since the July 2026 AACR D3 disclosure contained no patient counts or response rates. Note that near-term ACRV share-price action is driven by the ACR-368 Phase 2b prespecified interim analysis and all-comer serous endometrial cancer data guided for 2H 2026, not by ACR-2316, so any trade thesis should center on ACR-368 with ACR-2316 as upside optionality.
Price Chart
Executive Summary
ACR-2316 is Acrivon Therapeutics' (Nasdaq: ACRV) investigational dual WEE1/PKMYT1 inhibitor, described by the company as a potential first-in-class clinical-stage drug designed via its proprietary AP3 platform. Early data through mid-2026 show initial clinical activity (lung cancer) and early partial responses across multiple biomarker-predicted tumor types with favorable tolerability, though no quantitative efficacy figures have been released. It is a secondary program behind the company's lead asset ACR-368, and no regulatory binary for ACR-2316 is scheduled.
How It Works
Cancer cells with DNA damage normally pause their division so they can repair themselves, using two "checkpoint" proteins called WEE1 and PKMYT1. ACR-2316 blocks both proteins at once, forcing damaged cancer cells to divide prematurely and die. Acrivon says the drug was rationally designed with its AP3 (phosphoproteomics) platform to be potent on its own and to have a better safety window ("superior therapeutic index") than earlier WEE1-type drugs.
Trial Status
ACR-2316 is in an early clinical (dose-escalation-type) program. The July 21, 2026 AACR D3 conference press release highlighted "early clinical data" with early partial responses across multiple AP3-predicted tumor types and a favorable tolerability profile, without disclosing quantitative response rates or patient numbers. The Q4/FY2025 results release (March 19, 2026) cited "initial clinical activity" for ACR-2316 in lung cancer, and April 2026 AACR posters showed preclinical synergy with immune checkpoint inhibitors and ADC payloads.
The Two-Sided Case
Upcoming Catalysts
- Scientific-conference data updates on ACR-2316 Phase 1 dose escalation (no fixed date published; prior updates at AACR/AACR D3).
- Company-level, not drug-specific: ACR-368 Phase 2b prespecified interim analysis and all-comer serous endometrial cancer data, guided for 2H 2026 (Aug 12, 2026 release).
- Company-level: planned FDA IND submission for ACR-6840 in Q4 2026 (SEC-extracted catalyst, Mar 19, 2026).
- Next quarterly financial results (Q3 2026, typically ~November), which typically restate pipeline timing.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Acrivon Therapeutics, Inc Press Release ACRV ·Originating report